COMMUNIQUÉS West-GlobeNewswire

ERYTECH participera à plusieurs conférences d'investisseurs
13/09/2018
LYON, France, 13 sept. 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext : ERYP – Nasdaq : ERYP), société biopharmaceutique de stade clinique qui développe des thérapies innovantes en encapsulant des médicaments dans [...]
ESPERITE N.V. (ESP) WITH CRYOSAVE READY TO STORE MORE THAN A MILLION SAMPLES IN ITS NEW DESIGNED CRYOSTORAGE FACILITY IN GENEVA.
13/09/2018
CryoSave has fully equipped this new safe and secure sample storage BioBank in its state-of-the-art central laboratory in Geneva, Switzerland especially designed for optimal cryopreservation of all biological samples [...]
Novartis real-world evidence confirms efficacy and safety benefits of Cosentyx® in daily life for psoriasis patients
13/09/2018
Real-world evidence confirms Cosentyx ® efficacy and safety consistent with previously reported clinical studies [1]-[4] Novartis presents a large program of real-world evidence at the 27 th European Academy of [...]
Abeona Therapeutics annonce l'autorisation de commencer l'étude clinique de phase 1/2 sur la thérapie génique pour les patients atteints de MPS IIIB en Espagne
13/09/2018
Un essai clinique pour ABO-101 (AAV-NAGLU) marque le 2e programme MPS III en Europe La société prévoit de créer des sites cliniques supplémentaires dans certains pays européens, dont la France, l'Allemagne et le Royaume [...]
Galapagos raises $300 million gross proceeds in a U.S. public offering
13/09/2018
Mechelen, Belgium, 13 September 2018, 03.00 CET, regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announced today the pricing of its U.S. public offering totaling $ 300 million gross proceeds of 2,575, [...]
Xenon Pharmaceuticals Announces Pricing of $63.0 Million Public Offering of Common Shares
13/09/2018
BURNABY, British Columbia, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage, neurology-focused biopharmaceutical company, today announced the pricing of its underwritten [...]
XBiotech annonce l’arrivée d’un éminent cardiologue de renommée mondiale, le Dr. Peter Libby qui rejoint son Comité scientifique consultatif
13/09/2018
AUSTIN, Texas, 13 sept. 2018 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ : XBIT) a le plaisir d’annoncer la nomination au sein de son Comité scientifique consultatif de Peter Libby, MD. Le Dr. Libby travaillera avec [...]
Resverlogix Announces Voting Results from the 2018 Annual and Special Meeting of Shareholders
13/09/2018
CALGARY, Alberta, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX) today held its Annual and Special Meeting of Shareholders (the “Meeting”) in Calgary, Alberta. A [...]
Zenith Announces Voting Results from the 2018 Annual Meeting of Shareholders
13/09/2018
Archive of the Executive Presentation to be Posted to the Zenith Website CALGARY, Alberta, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Zenith Capital Corp. ("Zenith" or the "Company") announces that, at its annual meeting of [...]
Novartis announces NEJM publication of landmark PARADIGMS study demonstrating significant benefit of Gilenya® in children and adolescents with MS
12/09/2018
Treatment with Gilenya (fingolimod) substantially reduced the debilitating impact of MS, with significant decreases in key measures of disease activity vs. interferon beta-1a MS severely affects the everyday lives of [...]
Galapagos announces launch of proposed public offering
12/09/2018
Mechelen, Belgium, 12 September 2018, 22.45 CET, regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) announced today that it intends to offer and sell, subject to market and other conditions, $300 million [...]
Foamix Announces Proposed Follow-on Offering of Ordinary Shares
12/09/2018
REHOVOT, Israel, and BRIDGEWATER, N.J., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (“Foamix”) (Nasdaq: FOMX), a clinical-stage specialty pharmaceutical company focused on developing and [...]
Clearside Biomedical Appoints Viral Kansara as Vice President, Discovery
12/09/2018
ALPHARETTA, Ga., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye [...]
Adamas Announces New Employment Inducement Grant
12/09/2018
EMERYVILLE, Calif., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted six new employees the option [...]
Verrica Announces Successful Phase 2 Innovate Trial and Complete Enrollment of Phase 3 Trials of VP-102 in Molluscum Contagiosum Ahead of Schedule
12/09/2018
Innovate trial results reaffirm Phase 3 protocol design No serious adverse events (SAEs) reported during the Innovate trial Phase 3 pivotal trials for molluscum contagiosum fully enrolled and topline results now [...]
MorphoSys and Galapagos announce U.S. Antitrust Clearance for global license agreement for MOR106 with pharma partner
12/09/2018
Mechelen, Belgium and Planegg/Munich, Germany; 12 September 2018; 22.01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; NASDAQ: MOR) announced today the [...]
Xenon Pharmaceuticals Announces Proposed Public Offering of Common Shares
12/09/2018
BURNABY, British Columbia, Sept. 12, 2018 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage, neurology-focused biopharmaceutical company, today announced that it has commenced an [...]
Progenics Pharmaceuticals Reports Top Line Phase 3 Data for Prostate Cancer Imaging Agent 1404
12/09/2018
-Meets Co-Primary Endpoint of Specificity; 1404 Successfully Identifies Patients Without Clinically Significant Prostate Cancer- -Co-Primary Endpoint of Sensitivity to Identify Patients with Clinically Significant [...]
Présentation corporative de Pediapharm
12/09/2018
NE PAS DISTRIBUER AUX SERVICES DE TRANSMISSION DE NOUVELLES DES ÉTATS-UNIS NI DIFFUSER AUX ÉTATS-UNIS. LE NON-RESPECT DE CETTE RESTRICTION PEUT CONSTITUER UNE VIOLATION DE LA LÉGISLATION EN VALEURS MOBILIÈRES DES ÉTATS- [...]

Pages